Hepion Pharmaceuticals replaces auditor Grassi with Rosenberg Rich Baker Berman
Bitget2026/09/28 10:31- Hepion Pharmaceuticals dismissed auditor Grassi & Co. effective Sept. 22, 2026.
- Rosenberg Rich Baker Berman hired to audit 2026 consolidated financial statements.
- Prior audit reports included a going-concern warning tied to significant operating losses and negative operating cash flow since inception.
- Company reported no accounting or audit-scope disputes with Grassi for 2024-2025 or through Sept. 21, 2026.
- Material weaknesses in internal control over financial reporting were disclosed in recent filings, cited as the only reportable events.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
